BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas
Copyright © 2021 Elsevier Ltd. All rights reserved..
INTRODUCTION: Hodgkin's (HL) and non-Hodgkin's (NHL) lymphomas have usually high cure rates. The standard of care for chemosensitive relapsed/refractory lymphoma patients is salvage chemotherapy followed by AHSCT. Due to carmustine and melphalan shortages, alternative pre-AHSCT conditioning regimens with similar tolerance and response were needed.
OBJECTIVES: To compare the efficacy and toxicity profile between relapsed/refractory HL and NHL lymphomas given BEAM or BuCyE.
METHODS: A retrospective analyses of 122 patients in a Brazilian center was made. OS and PFS were calculated by Kaplan-Meier and compared by log rank. Toxicity and engraftment data were also compared.
RESULTS: Most clinical characteristics were similar between groups, although a higher frequency of grade ≥ 2 mucositis (p = .01) was seen in the BuCyE group. No significant difference in OS or PFS were observed between the groups.
CONCLUSION: BEAM and BuCyE are well tolerated with similar toxicity profiles and survival outcomes. Therefore, BuCyE conditioning regimen can be considered an alternative to BEAM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:110 |
|---|---|
| Enthalten in: |
Leukemia research - 110(2021) vom: 15. Nov., Seite 106689 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sapelli, Jaqueline [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.11.2021 Date Revised 29.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.leukres.2021.106689 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331341522 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331341522 | ||
| 003 | DE-627 | ||
| 005 | 20231225213242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.leukres.2021.106689 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM331341522 | ||
| 035 | |a (NLM)34592699 | ||
| 035 | |a (PII)S0145-2126(21)00190-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sapelli, Jaqueline |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2021 | ||
| 500 | |a Date Revised 29.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
| 520 | |a INTRODUCTION: Hodgkin's (HL) and non-Hodgkin's (NHL) lymphomas have usually high cure rates. The standard of care for chemosensitive relapsed/refractory lymphoma patients is salvage chemotherapy followed by AHSCT. Due to carmustine and melphalan shortages, alternative pre-AHSCT conditioning regimens with similar tolerance and response were needed | ||
| 520 | |a OBJECTIVES: To compare the efficacy and toxicity profile between relapsed/refractory HL and NHL lymphomas given BEAM or BuCyE | ||
| 520 | |a METHODS: A retrospective analyses of 122 patients in a Brazilian center was made. OS and PFS were calculated by Kaplan-Meier and compared by log rank. Toxicity and engraftment data were also compared | ||
| 520 | |a RESULTS: Most clinical characteristics were similar between groups, although a higher frequency of grade ≥ 2 mucositis (p = .01) was seen in the BuCyE group. No significant difference in OS or PFS were observed between the groups | ||
| 520 | |a CONCLUSION: BEAM and BuCyE are well tolerated with similar toxicity profiles and survival outcomes. Therefore, BuCyE conditioning regimen can be considered an alternative to BEAM | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a AHSCT | |
| 650 | 4 | |a BEAM | |
| 650 | 4 | |a BUCYE | |
| 650 | 4 | |a Conditioning regimens | |
| 650 | 4 | |a Relapsed lymphomas | |
| 650 | 7 | |a Cytarabine |2 NLM | |
| 650 | 7 | |a 04079A1RDZ |2 NLM | |
| 650 | 7 | |a Etoposide |2 NLM | |
| 650 | 7 | |a 6PLQ3CP4P3 |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a Busulfan |2 NLM | |
| 650 | 7 | |a G1LN9045DK |2 NLM | |
| 650 | 7 | |a Carmustine |2 NLM | |
| 650 | 7 | |a U68WG3173Y |2 NLM | |
| 700 | 1 | |a Filho, Jayr Schmidt |e verfasserin |4 aut | |
| 700 | 1 | |a Matias Vieira, Garles Miller |e verfasserin |4 aut | |
| 700 | 1 | |a Moura, Fernanda Lemos |e verfasserin |4 aut | |
| 700 | 1 | |a Germano, Janaina Naiara |e verfasserin |4 aut | |
| 700 | 1 | |a de Lima, Vladmir Cláudio Cordeiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia research |d 1991 |g 110(2021) vom: 15. Nov., Seite 106689 |w (DE-627)NLM000939560 |x 1873-5835 |7 nnns |
| 773 | 1 | 8 | |g volume:110 |g year:2021 |g day:15 |g month:11 |g pages:106689 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.leukres.2021.106689 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 110 |j 2021 |b 15 |c 11 |h 106689 | ||